Novo Nordisk Launches Wegovy Weight-Loss Pill for US Self-Pay Patients at $149/Month

Wegovy Pill Launch in the US

• 🚀 Novo Nordisk is launching its once-daily Wegovy weight-loss pill in the United States, with 1.5 mg and 4 mg doses available.
• 💰 The pill will be offered at $149 per month for self-paying patients.
• 🎯 The US Food and Drug Administration approved the pill last month, marking a significant development for Novo Nordisk.

Market Strategy and Competition

• ⚡ This launch provides a more flexible alternative to injectable medications like the injectable version of Wegovy and Eli Lilly's drugs.
• 📈 The company aims to regain ground in a competitive weight-loss drug market, especially after facing profit warnings and share declines last year.
• 💡 A key challenge will be attracting cash-paying consumers who lack insurance coverage, representing a shift from traditional insurance-managed drug pricing.

Dosing and Future Offerings

• 💊 The semaglutide pills contain the same active ingredient as injectable Wegovy and ampyra.
• 📈 Novo Nordisk also plans to offer 9 mg and a higher long-term dose of 25 mg, which will be priced at nearly $300 per month.